Want to see SNY full AI Analyst Report?
SNY Stock Chart & Stats
$43.35
$1.02(2.35%)
At close: 4:00 PM EDT
$43.35
$1.02(2.35%)
Day’s Range― - ―
52-Week Range$40.89 - $52.68
Previous CloseN/A
Volume449.65K
Average Volume (3M)3.79M
Market Cap
$110.67B
Enterprise Value$122.96K
Total Cash (Recent Filing)$6.35B
Total Debt (Recent Filing)$23.58B
Price to Earnings (P/E)24.1
Beta0.37
Next Earnings
Oct 30, 2026EPS Estimate
1.63Next Dividend Ex-DateN/A
Dividend Yield5.28%
Share Statistics
EPS (TTM)0.48
Shares Outstanding2,415,546,900
10 Day Avg. Volume3,058,074
30 Day Avg. Volume3,791,388
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.15
P/FCF Ratio9.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$53.00Price Target Upside22.26% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)4.92
Revenue Forecast (FY)$57.16B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthDouble-digit Q2 growth and upgraded full-year guidance indicate broad commercial momentum. Continued expansion, led by Pharma launches and Dupixent, can support durable revenue growth and improve operating leverage over the next several quarters.
Pipeline And Product ExpansionMultiple approvals and late-stage milestones broaden Sanofi’s future product base across oncology, vaccines, diabetes and rare disease. This reduces dependence on mature products and creates potential for sustained growth as new indications commercialize.
Conservative Balance SheetModerate leverage and substantial equity provide financial flexibility for research investment, business development and manufacturing needs. The balance sheet should help Sanofi absorb development risks while continuing to fund its pipeline and shareholder distributions.
Bears Say
Manufacturing And Supply ReliabilityRecurring shortages in Pompe therapies can disrupt patient treatment, sales and customer trust while increasing remediation costs. FDA-cited quality issues also raise execution risk for other products manufactured at or dependent on affected operations.
Margin And Cash-Flow VolatilityRevenue growth has not consistently translated into stronger operating profit, indicating pressure from costs or mix. Uneven earnings and cash conversion make performance less predictable and could constrain reinvestment if volatility persists.
Execution Risk From Strategic TransitionA broad leadership and operating-model transition may improve focus, but it also creates near-term execution risk across R&D, partnering, manufacturing and regional operations. Benefits from the restructuring may take time to emerge.
Sanofi News
SNY FAQ
What was Sanofi SA’s price range in the past 12 months?
Sanofi SA lowest stock price was $40.89 and its highest was $52.68 in the past 12 months.
What is Sanofi SA’s market cap?
Sanofi SA’s market cap is $110.67B.
When is Sanofi SA’s upcoming earnings report date?
Sanofi SA’s upcoming earnings report date is Oct 30, 2026 which is in 68 days.
How were Sanofi SA’s earnings last quarter?
Sanofi SA released its earnings results on Jul 30, 2026. The company reported $1.202 earnings per share for the quarter, beating the consensus estimate of $1.088 by $0.114.
Is Sanofi SA overvalued?
According to Wall Street analysts Sanofi SA’s price is currently Undervalued.
Does Sanofi SA pay dividends?
Sanofi SA pays a Annually dividend of $2.419 which represents an annual dividend yield of 5.28%. See more information on Sanofi SA dividends here
What is Sanofi SA’s EPS estimate?
Sanofi SA’s EPS estimate is 1.63.
How many shares outstanding does Sanofi SA have?
Sanofi SA has 2,415,546,900 shares outstanding.
What happened to Sanofi SA’s price movement after its last earnings report?
Sanofi SA reported an EPS of $1.202 in its last earnings report, beating expectations of $1.088. Following the earnings report the stock price went down -4.37%.
Which hedge fund is a major shareholder of Sanofi SA?
Currently, no hedge funds are holding shares in SNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanofi Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$53.00 (22.26% Upside)
$53.00 (22.26% Upside)
Blogger Sentiment
Bullish
SNY Sentiment 88%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.16%
12-Months-Change
Fundamentals
Return on Equity
5.28%
Trailing 12-Months
Asset Growth
0.59%
Trailing 12-Months
Company Description
Sanofi SA
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
SNY Company Deck
SNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive picture: strong top-line growth (9.9% FY, 13.3% Q4), robust launch performance (EUR 5.7bn from new products), significant pipeline delivery and regulatory progress, improved margins and free cash flow, plus strategic BD/M&A activity. Notable challenges include a Phase III failure for tolebrutinib, a safety case in the amlitelimab program that will require monitoring, decreased Regeneron R&D reimbursements (offset partly by higher royalties), and some uncertainty in the U.S. vaccine schedule and vaccine sales in 2026. Overall, positives (growth, profitability, launches, pipeline replenishment and balance sheet flexibility) outweigh the lowlights, though execution and regulatory/safety risks remain important to monitor.View all SNY earnings summariesSNY Stock 12 Month Forecast
Average Price Target
$53.00
▲(22.26% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.66% Mutual Funds
3.30% Other Institutional Investors
94.80% Public Companies and
Individual Investors